Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CAMBRIDGE, Mass., Jan. 03, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will present a company overview at the J.P. Morgan 35th Annual Healthcare Conference on Monday, January 9, 2017 at 12:00 p.m. PT. The conference is taking place January 9-12, 2017 at the Westin St. Francis in San Francisco.
To access the live webcast of Epizyme’s presentation, please visit the Events & Presentations page within the Investor page of the website at www.epizyme.com. Replays of the webcast will be available on the Epizyme website for 90 days following the conference.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Media Contact: Julie DiCarlo, Epizyme, Inc. (617) 306-5823 [email protected] Investor Contact: Monique Allaire, THRUST Investor Relations (617) 895-9511 [email protected]
